1. Home
  2. MDGL vs BYD Comparison

MDGL vs BYD Comparison

Compare MDGL & BYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • BYD
  • Stock Information
  • Founded
  • MDGL 2011
  • BYD 1973
  • Country
  • MDGL United States
  • BYD United States
  • Employees
  • MDGL N/A
  • BYD N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • BYD Hotels/Resorts
  • Sector
  • MDGL Health Care
  • BYD Consumer Discretionary
  • Exchange
  • MDGL Nasdaq
  • BYD Nasdaq
  • Market Cap
  • MDGL 6.1B
  • BYD 6.1B
  • IPO Year
  • MDGL N/A
  • BYD 1993
  • Fundamental
  • Price
  • MDGL $314.31
  • BYD $80.22
  • Analyst Decision
  • MDGL Strong Buy
  • BYD Buy
  • Analyst Count
  • MDGL 9
  • BYD 14
  • Target Price
  • MDGL $420.63
  • BYD $82.31
  • AVG Volume (30 Days)
  • MDGL 286.7K
  • BYD 1.3M
  • Earning Date
  • MDGL 08-06-2025
  • BYD 07-24-2025
  • Dividend Yield
  • MDGL N/A
  • BYD 0.84%
  • EPS Growth
  • MDGL N/A
  • BYD 9.82
  • EPS
  • MDGL N/A
  • BYD 6.13
  • Revenue
  • MDGL $317,383,000.00
  • BYD $3,961,238,000.00
  • Revenue This Year
  • MDGL $286.17
  • BYD $1.55
  • Revenue Next Year
  • MDGL $64.17
  • BYD $2.15
  • P/E Ratio
  • MDGL N/A
  • BYD $13.01
  • Revenue Growth
  • MDGL N/A
  • BYD 6.06
  • 52 Week Low
  • MDGL $200.63
  • BYD $52.76
  • 52 Week High
  • MDGL $377.46
  • BYD $87.76
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 64.53
  • BYD 56.69
  • Support Level
  • MDGL $284.02
  • BYD $80.42
  • Resistance Level
  • MDGL $311.21
  • BYD $87.76
  • Average True Range (ATR)
  • MDGL 11.94
  • BYD 2.00
  • MACD
  • MDGL 2.74
  • BYD 0.28
  • Stochastic Oscillator
  • MDGL 100.00
  • BYD 42.91

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About BYD Boyd Gaming Corporation

Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.

Share on Social Networks: